FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3084229101> ?p ?o ?g. }

• W3084229101 endingPage "E16" @default.
• W3084229101 startingPage "E16" @default.
• W3084229101 abstract "Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer, accounting for only 1-5% of breast cancer diagnoses but up to 10% of breast cancer deaths annually in the United States. In contrast to findings in non-IBC patients, prior studies of stage III IBC patients suggest that compared to other receptor subtypes, hormone receptor (HR) positivity is not a favorable prognostic factor. To compare overall survival between stage IV HR-positive IBC patients and their non-IBC counterparts in order to determine the prognostic value of HR positivity in stage IV IBC. We retrospectively examined 765 patients treated at MD Anderson Cancer Center and diagnosed between August 1987 and March 2012 with metastatic HR-positive breast cancer. Patient and tumor characteristics including HR quantitation were compared by IBC status. Differences between these subgroups were assessed using the chi-square test for categorical variables or a t-test for continuous measures. Compared to the to non-IBC cohort, stage IV HR-positive IBC patients were more likely to be PR-negative (65 vs. 77%, p=0.01). IBC patients were younger (median 48.5 vs. 55, p<0.001), more likely to have multiple metastases (48% vs. 38%, p=0.06), and less likely to have metastases to bone only (27% vs. 41%). Among all patients evaluated, those with visceral metastases had worse OS compared to those with bony metastases (2-year OS 75.1% vs 87.9%, p<0.001), as did those with multiple vs. single metastases (2-year OS 67.9% vs 88%, p<0.001). IBC patients had better performance status (100% vs. 93%, p=0.01) and were more likely to have definitive surgery (47% vs. 22%) and chemotherapy (89% vs. 45%, p<0.001). IBC patients were more likely to have received anthracyclines and taxanes (43% vs. 21% (p<0.001), 67% vs. 29% (p<0.001), respectively) and less likely to have first line hormonal therapy (6% vs. 49%, p<0.001). Overall survival at 2 years for HR-positive IBC vs. non-IBC patients was 76.9% vs. 81.0% (p=0.34). Exploring combined metrics of quantitative HR positivity, i.e., the sum, the difference, and the ratio of ER plus PR percentage, ER percentage (p=0.02), PR positivity and percentage (both p<0.001), HR sum (p<0.001) and ratio (p<0.001) but not difference (p=0.35) correlated to 2-year OS. PR positivity and qualitative PR percentage >9 correlated with a better 2-year OS (82.4% vs. 74.6% and 85% vs 72.7%, p<0.001). We found that while stage IV HR-positive IBC patients were more likely to have multiple metastases beyond the bone, they more commonly received chemotherapy rather than hormone-based regimens and achieved similar stage IV outcomes compared to non-IBC patients. These findings support our clinical practice offering trimodality therapy with systemic chemotherapy agents to HR-positive IBC patients." @default.
• W3084229101 created "2020-09-14" @default.
• W3084229101 creator A5014203493 @default.
• W3084229101 creator A5016582085 @default.
• W3084229101 creator A5016731809 @default.
• W3084229101 creator A5026202651 @default.
• W3084229101 creator A5027464426 @default.
• W3084229101 creator A5041793550 @default.
• W3084229101 creator A5053893309 @default.
• W3084229101 creator A5079431340 @default.
• W3084229101 creator A5088814426 @default.
• W3084229101 date "2020-10-01" @default.
• W3084229101 modified "2023-09-25" @default.
• W3084229101 title "Outcomes Among Hormone Receptor Positive Metastatic Inflammatory Breast Cancer (IBC)" @default.
• W3084229101 doi "https://doi.org/10.1016/j.ijrobp.2020.02.501" @default.
• W3084229101 hasPublicationYear "2020" @default.
• W3084229101 type Work @default.
• W3084229101 sameAs 3084229101 @default.
• W3084229101 citedByCount "0" @default.
• W3084229101 crossrefType "journal-article" @default.
• W3084229101 hasAuthorship W3084229101A5014203493 @default.
• W3084229101 hasAuthorship W3084229101A5016582085 @default.
• W3084229101 hasAuthorship W3084229101A5016731809 @default.
• W3084229101 hasAuthorship W3084229101A5026202651 @default.
• W3084229101 hasAuthorship W3084229101A5027464426 @default.
• W3084229101 hasAuthorship W3084229101A5041793550 @default.
• W3084229101 hasAuthorship W3084229101A5053893309 @default.
• W3084229101 hasAuthorship W3084229101A5079431340 @default.
• W3084229101 hasAuthorship W3084229101A5088814426 @default.
• W3084229101 hasBestOaLocation W30842291011 @default.
• W3084229101 hasConcept C121608353 @default.
• W3084229101 hasConcept C126322002 @default.
• W3084229101 hasConcept C143998085 @default.
• W3084229101 hasConcept C146357865 @default.
• W3084229101 hasConcept C151730666 @default.
• W3084229101 hasConcept C2775930923 @default.
• W3084229101 hasConcept C2780839634 @default.
• W3084229101 hasConcept C530470458 @default.
• W3084229101 hasConcept C71924100 @default.
• W3084229101 hasConcept C72563966 @default.
• W3084229101 hasConcept C86803240 @default.
• W3084229101 hasConceptScore W3084229101C121608353 @default.
• W3084229101 hasConceptScore W3084229101C126322002 @default.
• W3084229101 hasConceptScore W3084229101C143998085 @default.
• W3084229101 hasConceptScore W3084229101C146357865 @default.
• W3084229101 hasConceptScore W3084229101C151730666 @default.
• W3084229101 hasConceptScore W3084229101C2775930923 @default.
• W3084229101 hasConceptScore W3084229101C2780839634 @default.
• W3084229101 hasConceptScore W3084229101C530470458 @default.
• W3084229101 hasConceptScore W3084229101C71924100 @default.
• W3084229101 hasConceptScore W3084229101C72563966 @default.
• W3084229101 hasConceptScore W3084229101C86803240 @default.
• W3084229101 hasIssue "2" @default.
• W3084229101 hasLocation W30842291011 @default.
• W3084229101 hasOpenAccess W3084229101 @default.
• W3084229101 hasPrimaryLocation W30842291011 @default.
• W3084229101 hasRelatedWork W144521535 @default.
• W3084229101 hasRelatedWork W1562724462 @default.
• W3084229101 hasRelatedWork W2037999876 @default.
• W3084229101 hasRelatedWork W2070780645 @default.
• W3084229101 hasRelatedWork W2131242599 @default.
• W3084229101 hasRelatedWork W2411890706 @default.
• W3084229101 hasRelatedWork W2563193111 @default.
• W3084229101 hasRelatedWork W2979892935 @default.
• W3084229101 hasRelatedWork W3112166790 @default.
• W3084229101 hasRelatedWork W3181412252 @default.
• W3084229101 hasVolume "108" @default.
• W3084229101 isParatext "false" @default.
• W3084229101 isRetracted "false" @default.
• W3084229101 magId "3084229101" @default.
• W3084229101 workType "article" @default.